These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 15306684)

  • 1. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.
    Hohlfeld R; Wekerle H
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14599-606. PubMed ID: 15306684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies.
    Stinissen P; Raus J; Zhang J
    Crit Rev Immunol; 1997; 17(1):33-75. PubMed ID: 9034723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multiple sclerosis and experimental autoimmune encephalomyelitis].
    Béraud-Juven E
    Rev Prat; 1994 Jan; 44(1):69-74. PubMed ID: 8178062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein.
    de Rosbo NK; Ben-Nun A
    J Autoimmun; 1998 Aug; 11(4):287-99. PubMed ID: 9776706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mechanisms and experimental models of multiple sclerosis.
    Slavin A; Kelly-Modis L; Labadia M; Ryan K; Brown ML
    Autoimmunity; 2010 Nov; 43(7):504-13. PubMed ID: 20380590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
    Hermans G; Denzer U; Lohse A; Raus J; Stinissen P
    J Autoimmun; 1999 Sep; 13(2):233-46. PubMed ID: 10479392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides.
    Chou YK; Morrison WJ; Weinberg AD; Dedrick R; Whitham R; Bourdette DN; Hashim G; Offner H; Vandenbark AA
    J Immunol; 1994 Mar; 152(5):2520-9. PubMed ID: 7510747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.
    Olsson T; Zhi WW; Höjeberg B; Kostulas V; Jiang YP; Anderson G; Ekre HP; Link H
    J Clin Invest; 1990 Sep; 86(3):981-5. PubMed ID: 1697609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell vaccination as an immunotherapy for autoimmune diseases.
    Zhang J
    Cell Mol Immunol; 2004 Oct; 1(5):321-7. PubMed ID: 16285890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advances in pathogenesis and therapy of multiple sclerosis].
    Linker RA; Stadelmann C; Diem R; Bähr M; Brück W; Gold R
    Fortschr Neurol Psychiatr; 2005 Dec; 73(12):715-27. PubMed ID: 16355314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-based vaccines: the future of multiple sclerosis therapy?
    Stüve O; Cravens PD; Eagar TN
    Expert Rev Neurother; 2008 Mar; 8(3):351-60. PubMed ID: 18345967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy.
    Zhang J
    Crit Rev Immunol; 2001; 21(1-3):41-55. PubMed ID: 11642613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
    Stinissen P; Raus J
    Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T
    Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.
    Bourdette DN; Whitham RH; Chou YK; Morrison WJ; Atherton J; Kenny C; Liefeld D; Hashim GA; Offner H; Vandenbark AA
    J Immunol; 1994 Mar; 152(5):2510-9. PubMed ID: 7510746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.
    Martin R; McFarland HF
    Crit Rev Clin Lab Sci; 1995; 32(2):121-82. PubMed ID: 7598789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the immunopathogenesis of multiple sclerosis.
    Hellings N; Raus J; Stinissen P
    Immunol Res; 2002; 25(1):27-51. PubMed ID: 11868933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tovaxin for multiple sclerosis.
    Rivera VM
    Expert Opin Biol Ther; 2011 Jul; 11(7):961-7. PubMed ID: 21563876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.